Publications by authors named "Maricris Trillana"
Safety and immunogenicity of PIKA-adjuvanted recombinant SARS-CoV-2 spike protein subunit vaccine as a booster against SARS-CoV-2: a phase II, open-label, randomized, double-blinded study.
Renan James Lim Xiangyan Qiu Edison Alberto Maria Rosario Capeding Josefina Carlos Maricris Trillana
Clin Exp Vaccine Res
October 2024
Article Synopsis
- The study assessed the safety and effectiveness of a new COVID-19 booster vaccine (PIKA-adjuvanted recombinant) for adults who have already received two doses of an inactivated vaccine.
- Participants were divided into two groups: one received the PIKA vaccine, while the other got an inactivated vaccine, with their safety monitored and immune response measured through antibody levels over time.
- Results showed that the PIKA vaccine significantly increased neutralizing antibodies against both the Omicron variant and the original SARS-CoV-2 virus shortly after vaccination, although there was no long-term difference in antibody levels between the two vaccines after 90 days.